Pseudoephedrine News and Research

RSS

FDA approves Actavis ANDA for guaifenesin/pseudoephedrine tablets to relieve chest congestion

Actavis plc and its partner Perrigo Company plc announced today that Actavis has received U.S. Food and Drug Administration approval for its Abbreviated New Drug Application for guaifenesin/pseudoephedrine tablets and that Perrigo will begin shipments in time for the cough/cold season to its retail and wholesale customers in the U.S. The product will be packaged and marketed under store and proprietary brands and will be a high quality, value alternative to Mucinex® D tablets.

2 Jun 2015

Majority of Michiganders oppose prescription-only approach on popular medicines containing PSE

The Consumer Healthcare Products Association released the following statement today on a recent poll of Michigan voters conducted by The Tarrance Group and underwritten by CHPA.

24 Sep 2013

Longer looks: Fight against meth labs faces drug makers' opposition

Every week reporter Ankita Rao selects interesting reading from around the Web.

16 Aug 2013

CHPA praises signing into law of anti-methamphetamine bill

The Consumer Healthcare Products Association (CHPA) today applauded Ohio Governor John Kasich for signing into law House Bill 334, an anti-methamphetamine bill authored by Representative Terry Johnson (R-Portsmouth) and Representative Danny Bupb (R-West Union). With the new law, Ohio now becomes the 25th state to adopt real-time, stop-sale technology known as the National Precursor Log Exchange (NPLEx).

21 Dec 2012

NADDI lauds real-time, drug stop-sale system in North Carolina

The National Association of Drug Diversion Investigators (NADDI) – a nonprofit organization that facilitates cooperation between law enforcement, healthcare professionals, state regulatory agencies and pharmaceutical manufacturers in the prevention and investigation of drug diversion – today lauded the latest results achieved by the real-time, stop-sale system in North Carolina.

9 Jul 2012

Study provides evidence for meth abuse's causal effect on foster home admissions

Methamphetamine abuse leads to an increase in child abuse and neglect, which causes an increase in foster care admissions, according to a study from Baylor University.

3 Jul 2012

Idaho's adoption of NPLEx to block illegal methamphetamine sales receives praise

The Consumer Healthcare Products Association (CHPA) today applauded Idaho Governor C.L. "Butch" Otter for signing into law real-time, stop-sale technology called the National Precursor Log Exchange (NPLEx) which allows check-out clerks to block illegal pseudoephedrine purchases right at the point of sale and provides law enforcement with valuable criminal data up to the minute.

9 Apr 2012

Majority of Missourians continue to favor nonprescription access to PSE-containing medicines

The Consumer Healthcare Products Association (CHPA) released today a recent poll that found a majority of Missourians -- by a margin of 16 percent -- continue to favor nonprescription access to safe and effective medicines containing pseudoephedrine (PSE), such as Advil Cold & Sinus, Allegra-D, Claritin-D, Mucinex-D, and Sudafed over a prescription mandate.

7 Mar 2012

CHPA releases statement on new Oklahoma economic impact study

The Consumer Healthcare Products Association (CHPA) today released the following statement regarding a new economic impact study that analyzed the potential economic consequences a prescription requirement for safe and effective cold and allergy medicines containing pseudoephedrine (PSE) would have on the state of Oklahoma.

18 Feb 2012

State roundup: Ga., Minn. move slowly on exchanges

The entire Massachusetts congressional delegation is asking CMS to preserve the level of safety net funding and provider payments as the state tries to renew its Medicaid waiver. "We are concerned that changes proposed by CMS could significantly threaten payments to Massachusetts health care providers providing care for the most vulnerable populations," Sens. John Kerry and Scott Brown and the 10 House members in the state's delegation wrote.

2 Nov 2011

Drug use among young adults on the rise in U.S.

Nearly one in 10 Americans report regularly using illegal drugs, including marijuana, cocaine, heroin, hallucinogens, inhalants or prescription drugs used recreationally, according to the National Survey on Drug Use and Health made public today. The survey, sponsored by the federal Substance Abuse and Mental Health Services Administration (SAMHSA), collects the data from interviews with 67,500 randomly selected people 12 years or older.

12 Sep 2011

New meta-analysis reaffirms safety profile of aspirin for pain relief, fever

A new meta-analysis published this week in Drugs in R&D, reaffirms the safety profile of aspirin for short-term treatment of mild to moderate pain, and aches and fever due to colds when used as directed.

2 Sep 2011

U.S. District Court rules in favor of Watson over Mucinex patent suit

Watson Pharmaceuticals, Inc. today confirmed that the United States Court of Appeals for the Federal Circuit has affirmed the United States District Court for the Southern District of Florida's February 2011 decision that Watson's generic versions of Mucinex(R), Mucinex(R) D, and Mucinex(R) DM Extended-Release products do not infringe U.S. Patent No. 6,372,252.

8 Jul 2011

Cypress receives FDA approval for ZUTRIPRO, REZIRA NDA to treat cough and common cold

Cypress Pharmaceutical announced today that the Food and Drug Administration (FDA) approved a new drug application (NDA) for ZUTRIPRO Oral Solution (CIII) and REZIRA Oral Solution.

14 Jun 2011

Dr. Reddy's 2011 consolidated revenues increase 6% to Rs. 74.7 billion

Dr. Reddy's Laboratories Ltd. today announced its unaudited consolidated financial results for the quarter and full year ended March 31, 2011 under International Financial Reporting Standards.

13 May 2011

SCOLR Pharma total revenue decreases 34% to $618,000 for 2010

SCOLR Pharma, Inc. today reported financial results for the twelve months ended December 31, 2010, and also provided updates on a number of key corporate objectives.

30 Mar 2011

SCLR announces FDA's issue of deficiency letter for pseudoephedrine ANDA

SCOLR Pharma, Inc. today announced it has received a letter from the Food and Drug Administration identifying deficiencies regarding its Abbreviated New Drug Application for extended-release pseudoephedrine.

14 Mar 2011

Florida pain clinic society opposes Gov. Scott's proposal to repeal Prescription Drug Monitoring Program

The Florida Society of Pain Management Providers opposes Governor Scott's proposal to repeal the Prescription Drug Monitoring Program (PDMP). The PDMP system is the single most important weapon in the war on Rx drug abuse, not only in Florida but in the other 42 states where legislators have approved their operation.

10 Feb 2011

US District Court rules in favor of Watson in generic Mucinex patent infringement suit

Watson Pharmaceuticals, Inc., a leading specialty pharmaceutical company, announced today that the United States District Court for the Southern District of Florida has ruled that Watson's generic versions of Mucinex®, Mucinex® D and Mucinex® DM (Guaifenesin, Dextromethorphan HBr/ Guaifenesin, and Pseudoephedrine/Guaifenesin) Extended-Release products, do not infringe U.S. Patent No. 6,372,252.